AtriCure Stock Forecast, Price & News

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AtriCure in the last year. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AtriCure stock.
View analyst ratings for AtriCure or view top-rated stocks.

Wall Street analysts have given AtriCure a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but AtriCure wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

AtriCure saw a drop in short interest during the month of August. As of August 13th, there was short interest totaling 919,300 shares, a drop of 33.4% from the July 29th total of 1,380,000 shares. Based on an average daily trading volume, of 280,600 shares, the days-to-cover ratio is currently 3.3 days. Currently, 2.1% of the company's stock are sold short.
View AtriCure's Short Interest.

AtriCure is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for AtriCure.

AtriCure, Inc. (NASDAQ:ATRC) issued its quarterly earnings results on Tuesday, August, 3rd. The medical device company reported ($0.36) EPS for the quarter, missing analysts' consensus estimates of ($0.30) by $0.06. The medical device company earned $71.38 million during the quarter, compared to analyst estimates of $61.08 million. AtriCure had a negative trailing twelve-month return on equity of 10.18% and a negative net margin of 23.31%. AtriCure's revenue for the quarter was up 74.8% on a year-over-year basis. During the same period last year, the company posted ($0.38) EPS.
View AtriCure's earnings history.

AtriCure's stock was trading at $35.28 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ATRC shares have increased by 114.9% and is now trading at $75.80.
View which stocks have been most impacted by COVID-19.

AtriCure updated its FY 2021 earnings guidance on Wednesday, September, 1st. The company provided earnings per share guidance of $-1.200-$-1.200 for the period, compared to the Thomson Reuters consensus EPS estimate of $-1.250. The company issued revenue guidance of $270 million-$275 million, compared to the consensus revenue estimate of $254.77 million.

8 Wall Street analysts have issued 12 month price objectives for AtriCure's stock. Their forecasts range from $75.00 to $120.00. On average, they expect AtriCure's stock price to reach $89.00 in the next twelve months. This suggests a possible upside of 17.4% from the stock's current price.
View analysts' price targets for AtriCure or view top-rated stocks among Wall Street analysts.

25 employees have rated AtriCure CEO Michael Carrel on Glassdoor.com. Michael Carrel has an approval rating of 100% among AtriCure's employees. This puts Michael Carrel in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to AtriCure include Abbott Laboratories (ABT), Medtronic (MDT), Intuitive Surgical (ISRG), Stryker (SYK), Becton, Dickinson and (BDX), Edwards Lifesciences (EW), Boston Scientific (BSX), IDEXX Laboratories (IDXX), DexCom (DXCM), ResMed (RMD), Baxter International (BAX), STERIS (STE), Insulet (PODD), Hologic (HOLX) and Teleflex (TFX).
View all of ATRC's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other AtriCure investors own include AbbVie (ABBV), Gilead Sciences (GILD), Amgen (AMGN), Vertex Pharmaceuticals (VRTX), Enterprise Products Partners (EPD), Abbott Laboratories (ABT), Neurocrine Biosciences (NBIX), NVIDIA (NVDA), Pfizer (PFE) and Sarepta Therapeutics (SRPT).

AtriCure trades on the NASDAQ under the ticker symbol "ATRC."

AtriCure's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (9.15%), BlackRock Inc. (8.03%), Alliancebernstein L.P. (6.21%), Invesco Ltd. (5.03%), Price T Rowe Associates Inc. MD (4.73%) and Champlain Investment Partners LLC (3.40%). Company insiders that own AtriCure stock include Angela L Wirick, David D Jr Grumhaus, Douglas J Seith, Justin J Noznesky, Justin J Noznesky, M Andrew Wade, Mark A Collar, Mark A Collar, Michael H Carrel, Regina E Groves, Salvatore Privitera, Scott William Drake, Sven Wehrwein, Tonya Austin and Vinayak Doraiswamy.
View institutional ownership trends for AtriCure.

ATRC stock was sold by a variety of institutional investors in the last quarter, including Champlain Investment Partners LLC, FMR LLC, TimesSquare Capital Management LLC, Wasatch Advisors Inc., BlackRock Inc., Eagle Asset Management Inc., Neuberger Berman Group LLC, and Bellevue Group AG. Company insiders that have sold AtriCure company stock in the last year include Angela L Wirick, David D Jr Grumhaus, Douglas J Seith, Justin J Noznesky, Mark A Collar, Michael H Carrel, Regina E Groves, Salvatore Privitera, Scott William Drake, Sven Wehrwein, Tonya Austin, and Vinayak Doraiswamy.
View insider buying and selling activity for AtriCure or view top insider-selling stocks.

ATRC stock was purchased by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Alliancebernstein L.P., Macquarie Group Ltd., Dimensional Fund Advisors LP, Thornburg Investment Management Inc., Principal Financial Group Inc., Castleark Management LLC, and Brinker Capital Investments LLC.
View insider buying and selling activity for AtriCure or or view top insider-buying stocks.

Shares of ATRC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ATRC stock can currently be purchased for approximately $75.80.

AtriCure has a market capitalization of $3.48 billion and generates $206.53 million in revenue each year. The medical device company earns $-48,150,000.00 in net income (profit) each year or ($1.01) on an earnings per share basis.

AtriCure employs 750 workers across the globe.

The following companies are subsidiares of AtriCure: SentreHEART.

AtriCure was founded in 2000.

The official website for AtriCure is www.atricure.com.

AtriCure is headquartered at 7555 INNOVATION WAY, MASON OH, 45040.

AtriCure's mailing address is 7555 INNOVATION WAY, MASON OH, 45040. The medical device company can be reached via phone at (513) 755-4100.